Background: Bacterial infection of the lower respiratory tract initiates an acute inflammatory response. Regulation of the inflammatory response in bacterial pneumonia depends on a complex interaction between immune cells and inflammatory cytokines. Objectives: We investigated the initial levels of proinflammatory cytokines and acute phase reactants (APR), e.g. C-reactive protein (CRP), upon presentation of community-acquired pneumonia (CAP) in relation to clinical and laboratory indices of infection. Methods: We prospectively studied 28 consecutive patients with unilateral CAP. Tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and IL-8 concentrations were measured by ELISA in both bronchoalveolar lavage (BAL) fluid and serum. Results: The concentrations of IL1-β and IL-6 in BAL fluid were found to be significantly higher in the involved lung than those in either the noninvolved lung (p = 0.008 and p = 0.012, respectively) or serum (p = 0.002 and p = 0.025, respectively). Serum CRP concentrations were increased compared to those in the involved and noninvolved lung in BAL fluid (p = 0.000 and p = 0.000, respectively). In serum and BAL from involved lung, IL-6 concentrations were higher in the systemic inflammatory response syndrome (SIRS) group than in the non-SIRS group (p < 0.05), whereas CRP, TNF-α , IL-1β and IL-8 concentrations showed no difference between SIRS and non-SIRS. There was no significant correlation between the acute physiology and chronic health evaluation II score and the cytokines. Conclusions: Our results indicate that the CRP level is higher in the serum than in the BAL fluid in the lung, and that IL-6 is the most important cytokine for the determination of the severity of the disease.

Keywords:
Bronchoalveolar lavage fluid, C-reactive protein, Pneumonia, Cytokine levels, serum
1.
American Thoracic Society: Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001;163:1730–1754.
2.
Dehoux MS, Boutten A, Ostinelli J, et al: Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1994;150:710–716.
3.
Yalçin M, Bardak M: The distribution of hospitalized patients (according to A list) in Turkey, 1995. Health Statistics 1996. Aydoğdu Ofset-Ankara, publication No.595, November 1997, pp 54–59.
4.
Monton C, Torres A, El-Ebiary M, Filella X, Xaubet A, Bellacasa JP: Cytokine expression in severe pneumonia: A bronchoalveolar lavage study. Crit Care Med 1999;27:1745–1753.
5.
Nelson S, Mason CM, Kolls J, Summer WR: Pathophysiology of pneumonia. Clin Chest Med 1995;16:1–12.
6.
Sibille Y, Reynolds HY: Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 1990;141:471–501.
7.
Puren AJ, Feldman C, Savage N, Becker PJ, Smith C: Patterns of cytokine expression in community acquired pneumonia. Chest 1995;107:1342–1349.
8.
Strieter RM, Miller EJ, Kurdowska AK, Reid PT, Donnelly SC: Measurement of cytokines in bronchoalveolar lavage fluid. Eur Respir Rev 1999;66:106–112.
9.
Meduri GU, Headley S, Kohler G, et al: Persistent elevation of inflammatory cytokines predicts a poor outcome in ARDS: Plasma IL1β and IL6 levels are consistent and efficient predictors of outcome over time. Chest 1995;107:1062–1073.
10.
Boutten A, Dehoux MS, Seta N, et al: Compartmentalized IL8 and elastase release within the human lung in unilateral pneumonia. Am J Respir Crit Care Med 1996;153;336–342.
11.
Meduri GU, Kohler G, Headley S, et al: Inflammatory cytokines in the BAL of patients with ARDS. Chest 1995;108:1303–1314.
12.
Weingarten SR, Riedinger MS, Hobson P, et al: Evaluation of a pneumonia practice guideline in an interventional trial. Am J Respir Crit Care Med 1996;153:1110–1115.
13.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–1655.
14.
Campbell GD: Overview of community-acquired pneumonia: Prognosis and clinical features (review). Med Clin North Am 1994;78:1035–1048.
15.
American Thoracic Society: Clinical role of bronchoalveolar lavage in adults with pulmonary disease. Am Rev Respir Dis 1990;142:481–486.
16.
The CB0006 Sepsis Syndrome Study Group: Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318–327.
17.
Chollet-Martin S, Montravers P, Gibert C, et al: High levels of interleukin 8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect Immun 1993;61:4553–4559.
18.
Grünewald T, Schüler-Maue W, Ruf B: Interleukin 8 and granulocyte stimulating factor in bronchoalveolar lavage fluid and plasma of human immunodeficiency virus infected patients with Pneumocystis carinii pneumonia, bacterial pneumonia or tuberculosis. J Infect Dis 1993;168:1077–1078.
19.
Kosmas EN, Baxevanis CN, Papamichail M, Kordossis T: Daily variation in circulating cytokines and acute phase proteins correlates with clinical and laboratory indices in community acquired pneumonia. Eur J Clin Invest 1997;27:308–315.
20.
Kwak DJ, Augustine NH, Borges WG, Joyner JL, Green WF, Hill HR: Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci. Infect Immun 2000;68:320–327.
21.
Benfield TL, Vestbo J, Junge J, Nielsen TL, Jensen AM, Lundgren JD: Prognostic value of interleukin 8 in AIDS associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995;151:1058–1062.
22.
Herman JL, Blanchard H, Brunengo P, Lagrange PH: TNFα, IL1β and IL6 levels in neutropenic patients after onset of fever and correlation with the C reactive protein (CRP) kinetic values. Infection 1994;22:309–315.
23.
Marik PE: The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000;15:85–90.
24.
Bauer TT, Monton C, Torres A, et al: Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls. Thorax 2000;55:46–52.
25.
Krarup E, Vestbo J, Benfield TL, Lundgren JD: Interleukin-8 and leukotriene B4 in bronchoalveolar lavage fluid from HIV-infected patients with bacterial pneumonia. Respir Med 1997;91:317–321.
26.
Glynn P, Coakley R, Kilgallen I, Murphy N, O’Neill S: Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999;54:51–55.
27.
Steel DM, Whitehead AS: The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today 1994;15:81–88.
28.
Baumann H, Gauldie J: The acute phase response. Immunol Today 1994;15:74–80.
29.
Galve-de Rochemonteix BG, Wiktorowicz K, Kushner I, Dayer JM: C-reactive protein increases production of IL-1α, IL-1β, and TNF-α, and expression of mRNA by human alveolar macrophages. J Leukoc Biol 1993;53:439–445.
30.
Sheldon J, Riches P, Gooding R, Soni N, Hobbs JR: C-reactive protein and its cytokine mediators in intensive-care patients. Clin Chem 1993;39:147–150.
31.
Dinarello CA: The proinflammatory cytokines interleukin 1 and tumor necrosis factor and the treatment of septic shock syndrome. J Infect Dis 1991;163:1177–1184.
32.
Toikka P, Irjala K, Juven T, et al: Serum procalcitonin, C-reactive protein and interleukin-6 for distinguishing bacterial and viral pneumonia in children. Pediatr Infect Dis J 2000;19:598–602.
© 2003 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.